News from takeda pharmaceutical company limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

30 Jul, 2015, 07:00 BST Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1%

Guidance for FY2015 confirmed, including Core Earnings and Core EPS Highlights of Q1 results Underlying revenue +6.1% year-to-year (reported revenue...


27 Jul, 2015, 11:00 BST DNDi and Takeda Collaborate for the Lead Optimization for Aminopyrazole Series for Visceral Leishmaniasis

Drugs for Neglected Diseases initiative (Headquarters: Geneva, Switzerland; Executive Director: Bernard Pécoul, Doctor; "DNDi") and Takeda...


05 Jun, 2015, 22:35 BST Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Takeda Pharmaceutical Company Limited, ("Takeda") today announced additional post-hoc analyses from the global EXAMINE (EXamination of CArdiovascular ...


15 May, 2015, 07:26 BST Takeda Reports Top Line Results in Line With Guidance, With Underlying Growth of +2.8% EPS Affected by One-time Charges in FY2014 Back to Profitable Growth from FY2015 Onward

Operational guidance met Underlying revenue +2.8% year-over-year, in line with guidance (reported revenue growing +5.1% to 1,777.8 billion yen)...


09 Mar, 2015, 23:01 GMT Takeda Announces Publication in The Lancet of a Post Hoc Analysis of Data from the EXAMINE Cardiovascular Safety Outcomes Trial

Takeda Pharmaceutical Company Limited (Takeda) announced that a post hoc analysis of data from the global EXAMINE (EXamination of CArdiovascular...


09 Mar, 2015, 17:15 GMT Takeda Hosts Investor Briefing on its Global Leadership in Gastroenterology

Takeda Pharmaceutical Company Limited ("Takeda") today held a briefing for investors and analysts in New York, discussing the company's...


28 Aug, 2014, 17:51 BST Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from a...


27 May, 2014, 15:43 BST Takeda Receives European Commission Marketing Authorisation for Entyvio(R) (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European...


27 May, 2014, 13:11 BST Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European...


27 Mar, 2014, 12:00 GMT Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN...


21 Mar, 2014, 12:38 GMT Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited ("Takeda") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...


08 Jan, 2014, 06:15 GMT Takeda's New Investigational Drug Vedolizumab Entered Phase 3 Clinical Trials in Japan For the Treatment of Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited ("Takeda") announced today that vedolizumab (development code: MLN0002), an investigational drug for the...


24 Sep, 2013, 07:00 BST Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, Vipidia[TM] ▼ (alogliptin) and Fixed-Dose Combinations Vipdomet[TM] ▼ (alogliptin and metformin) and Incresync[TM] ▼ (alogliptin and pioglitazone)

Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for Vipidia[TM]...


21 Aug, 2013, 22:40 BST Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited ("Takeda") today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational...


09 May, 2013, 07:15 BST Takeda Pharmaceutical Company Limited Announces Financial Results for the Fiscal Year Ended March 31, 2013 and Forecasts for the Fiscal Year Ending March 31, 2014

Takeda Pharmaceutical Company Limited ("Takeda", "the Company") announced today the consolidated financial results for the fiscal year ended March...


08 Mar, 2013, 10:00 GMT Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union

 Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The...


28 Jan, 2013, 07:00 GMT Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)

Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. announced that the United States...


04 Sep, 2012, 12:00 BST Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)

SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications....


19 Jun, 2012, 13:33 BST Takeda Announces Acceptance of European Medicines Agency Submissions for Two Fixed-Dose Combination Therapies, Alogliptin and Pioglitazone and Alogliptin and Metformin, for the Treatment of Type 2 Diabetes

Takeda Pharmaceutical Company Limited (Takeda) Ltd. today announced that Takeda Global Research & Development Centre (Europe) Ltd. ("TGRD Europe")...


25 May, 2012, 09:19 BST Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil

 Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. (Rio Grande do...


23 May, 2012, 12:24 BST Takeda Announces the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes

Takeda Pharmaceutical Company Ltd. (Takeda) today announced that Takeda Global Research & Development Centre (Europe) Ltd. ("TGRD Europe") received...


27 Feb, 2012, 08:00 GMT Takeda Announces Acceptance of European Marketing Authorisation Application for Peginesatide, an Investigational Compound for the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

Takeda Pharmaceutical Company Limited (Takeda) today announced that Takeda Global Research & Development Centre (Europe) Ltd received confirmation of ...


18 Jan, 2012, 09:00 GMT Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth

Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced today strategic measures to better align its global workforce and consolidate...


10 Jan, 2012, 07:00 GMT European Commission Adopts European Medicines Agency's Opinion Confirming Pioglitazone-Containing Medicines Remain a Valid Treatment Option for Appropriate Type 2 Diabetes Patients

European Commission review is now concluded following the adoption of the CHMP Opinion made in October 2011 Takeda Pharmaceutical Company Limited...